The Expanding Role of Biosimilar in Autoimmune Diseases

The advent of biosimilar has significantly transformed the therapeutic landscape of autoimmune diseases. These agents, developed to be highly similar to approved biologic reference products, offer comparable efficacy and safety at reduced costs. Their introduction has facilitated broader access to biologic treatments, improved healthcare sustainability, and stimulated competition in the pharmaceutical industry. This review explores the development, regulatory frameworks, clinical applications, safety profiles, challenges, and future directions of biosimilar in the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.